Corporate Information
Management & Advisory Teams
Licensing & Co-Development Opportunities

 

Mission Statement

Galmed Medical Research develops innovative, proprietary drugs for the treatment of chronic lipid  related diseases. The company has developed a series of proprietary fatty acid bile-acid conjugates (FABACs) which selectively effect several pathways in lipid metabolism, as demonstrated in several species in vivo and in human cells and tissues in vitro.
The company’s flagship clinical compound Aramchol  (arachidyl amido cholanoic acid), for the treatment of Non Alcoholic Fatty Liver and Steatohepatitis (NAFLD & NASH, respectively) has completed Phase I studies in Humans and is about to start Phase IIa Studies.

 


 

 

GalMed’s novel proprietary products and technology offer a new therapeutic management of chronic diseases related to lipid disorders and is expected to play a major role as an innovative mover in these emerging markets.

 

Milestones
Galmed is seeking a partnership / licensing arrangement in order to participate in compound development.

At present the company is advancing in several fronts:

• Advancement of Aramchol towards Phase-II clinical trial in patient populations.
• Selection of future preclinical candidates for liver dependent therapeutic indications.
• Establishment of a chemical and biological program to evaluate centrally active
   compounds for brain disorders that are related to lipid metabolism. 

                            
  
 
 

Back to Top